Clinical efficacy evaluation and long-term prognosis of glucagon-like peptide-1 combined with sodium glucose cotransporter-2 inhibitor in diabetes
By: Yan, Pi
.
Contributor(s): Ting, Ting Du.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2022Edition: Vol.84(4), Jul-Aug.Description: 812-820p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical sciencesSummary: To investigate the clinical worth of glucagon-like peptide-1 receptor agonist (liraglutide) combined with
sodium glucose cotransporter-2 inhibitor (dapagliflozin) in the treatment of overweight or obesity patients
with type 2 diabetes mellitus and to explore whether the beneficial effect of the combination can persist
during a 1 y follow-up. Eighty overweight or obesity type 2 diabetes mellitus patients admitted to a hospital
from January 2019 to January 2020 were randomly divided into a control group and an observation group,
with 40 cases in each group. The control group was treated with liraglutide and the experimental group
was treated with basic dapagliflozin in the control group. All patients were continuously treated for 12 w.
The measurement results of parameters before and after treatment, the changes in glucose metabolism
parameters, blood lipid metabolism parameters and the occurrence of adverse reactions during treatment
were recorded. After that, 74 treated patients were followed up for 1 y (6 refused) and measurements of
various parameters were recorded. The differences in body mass index, waist circumference, hemoglobin
A1c, fasting plasma glucose, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol, homeostatic model assessment-insulin resistance, homeostatic model
assessment-beta and insulin sensitivity index before and after treatment in the experimental group were
higher than those in the control group (p<0.05). Weight loss during treatment was sustained over 1 y in
both groups, with more significant changes in the experimental group. The combination of glucagon-like
peptide-1 agonist and sodium glucose cotransporter-2 inhibitor can improve diabetes in overweight or
obesity patients with type 2 diabetes mellitus and effectively reduce blood glucose and body mass index,
which is of great significance for reducing body weight and improving efficacy. Therefore, using glucagon-
like peptide-1 agonists and sodium glucose cotransporter-2 inhibitors in overweight, diabetic patients is a
promising option.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2023-0838 |
To investigate the clinical worth of glucagon-like peptide-1 receptor agonist (liraglutide) combined with
sodium glucose cotransporter-2 inhibitor (dapagliflozin) in the treatment of overweight or obesity patients
with type 2 diabetes mellitus and to explore whether the beneficial effect of the combination can persist
during a 1 y follow-up. Eighty overweight or obesity type 2 diabetes mellitus patients admitted to a hospital
from January 2019 to January 2020 were randomly divided into a control group and an observation group,
with 40 cases in each group. The control group was treated with liraglutide and the experimental group
was treated with basic dapagliflozin in the control group. All patients were continuously treated for 12 w.
The measurement results of parameters before and after treatment, the changes in glucose metabolism
parameters, blood lipid metabolism parameters and the occurrence of adverse reactions during treatment
were recorded. After that, 74 treated patients were followed up for 1 y (6 refused) and measurements of
various parameters were recorded. The differences in body mass index, waist circumference, hemoglobin
A1c, fasting plasma glucose, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol, homeostatic model assessment-insulin resistance, homeostatic model
assessment-beta and insulin sensitivity index before and after treatment in the experimental group were
higher than those in the control group (p<0.05). Weight loss during treatment was sustained over 1 y in
both groups, with more significant changes in the experimental group. The combination of glucagon-like
peptide-1 agonist and sodium glucose cotransporter-2 inhibitor can improve diabetes in overweight or
obesity patients with type 2 diabetes mellitus and effectively reduce blood glucose and body mass index,
which is of great significance for reducing body weight and improving efficacy. Therefore, using glucagon-
like peptide-1 agonists and sodium glucose cotransporter-2 inhibitors in overweight, diabetic patients is a
promising option.
Click on an image to view it in the image viewer
There are no comments for this item.